Healthcare stocks outperform broader market since October | Healthcare Asia Magazine
, Hong Kong

Healthcare stocks outperform broader market since October

GLP-1 drugs' potential propelled healthcare stocks trading.

Hang Seng Hong Kong-listed Biotech Index reported 10.1% growth since October following growing attraction in GLP-1 drugs, which treat diabetes and obesity.

Healthcare stocks have outperformed other industries and the broader market since October, driven by the potential of GLP-1 drugs for treating diabetes and obesity.

A Lancet study forecast that by 2030, the prevalence of overweight and obesity in China could reach 65.3% in adults, leading to significant medical costs.

HSHKBIO, representing the 50 largest Hong Kong-listed biotech companies, reported a cumulative gain of over 10% since October, outperforming the broader market by 13 percentage points. The index's top subsector is biotechnology, comprising 44% of its weighting, while pharmaceuticals account for 40%.

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!